Formulated Methylene Blue
Phase 3Small molecule
Formulated Methylene Blue is one of 62 small molecule programs targeting Basal Cell Carcinoma. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
61
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
69 competitors in Squamous Cell Carcinoma
#DrugCompanyPhaseTrials
1Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Keytruda
Merck & Co.Phase 3
Erbitux
IImclone
Phase 3
Actos
TakedaApproved
Opdivo
Bristol-Myers SquibbPhase 3
Taxol
TevaPhase 3
Paraplatin
AAvyxa
Phase 3
Tecentriq
RochePhase 3
Libtayo
RegeneronPhase 3
Yervoy
Bristol-Myers SquibbPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Basal Cell Carcinoma1 trial
Treatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene Blue
Enrolling by invitation·—·Phase 3·NCT07311070·20 enrolled
Squamous Cell Carcinoma1 trial
Investigation of Effect of Formulated Methylene Blue on Treatment of Squamous Cell Carcinoma Skin Cancer in Inoperable Patients and Not Suitable for Radiotherapy
Enrolling by invitation·—·Phase 3·NCT07311057·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Formulated Methylene Blue. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- DDaryoush Hamidi Alamdari, PhD